Clinical trials: Cancer of Skin
Cutaneous Melanoma, Stage III, Cutaneous Melanoma, Stage IV
pDNA Intralesional Cancer Vaccine for Cutaneous Melanoma
Six patients will receive IFx-Hu2.0 on an outpatient basis at a single time point in a single lesion, two lesions, or three lesions, as a monotherapy (a maximum of three lesions could be injected).
- Trial name
- NCT03655756
- Testing
- IFx-Hu2.0
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- TuHURA Biosciences, Inc.
Breast Neoplasms
Study Evaluating Temsirolimus (CCI-779) In Breast Neoplasms
To evaluate the preliminary activity and pharmacokinetics of 2 separate doses and schedules of orally administered Temsirolimus (CCI-779) given in combination with daily letrozole, compared to letrozole alone, in the treatment of…
- Trial name
- NCT00062751
- Testing
- Letrozole / Temsirolimus (CCI-779), Letrozole
- Volunteers
- 108 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Lymphedema, Breast Cancer
Arm Circumference Measurement With or Without Bioimpedance Spectroscopy in Finding Lymphedema Early in Patients With Stage I-III Breast Cancer
This randomized pilot clinical trial studies arm circumference measurement with or without bioimpedance spectroscopy in finding extra lymph node fluid build up in the arm (lymphedema) early in patients with stage I-III breast…
- Trial name
- NCT03648983
- Testing
- arm circumference measurement, Bioimpedance spectroscopy
- Where
- United States
- Volunteers
- 95 people
- Sponsor
- Albert Einstein College of Medicine
Breast Cancer
Phase 2 Anastrozole and Vandetanib (ZD6474) in Neoadjuvant Treatment of Postmenopausal Hormone Receptor-Positive Breast Cancer
In this study we plan to study the combination of ZD6474, a dual inhibitor of EGFR and VEGFR-2 with anastrozole in the neoadjuvant setting for patients with Stage I-III breast cancer.
- Trial name
- NCT00481845
- Testing
- Vandetanib, Anastrozole
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Stanford University
Breast Cancer
PET-MR for Prediction and Monitoring of Response to Neoadjuvant Chemotherapy in Breast Cancer
The purpose of this study is: To validate the efficacy of multiparametric MRI, FDG-PET, RGD-PET, and PET-MR fusion imaging in the prediction and monitoring response to neoadjuvant chemotherapy of locally advanced breast cancer…
- Trial name
- NCT01190566
- Where
- South Korea
- Volunteers
- 57 people
- Sponsor
- Seoul National University Hospital
Triple-negative Breast Cancer
A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer
This is a global Phase III, double-blind, randomized, placebo-controlled study designed to evaluate the efficacy and safety of neoadjuvant treatment with atezolizumab (anti-programmed death-ligand 1 [anti-PD-L1] antibody) and…
- Trial name
- IMpassion031 (NCT03197935)
- Testing
- Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody, Nab-paclitaxel, Doxorubicin
- Where
- 68 sites in United States, Australia and 11 more
- Volunteers
- 333 people
- Sponsor
- Hoffmann-La Roche
Metastatic Melanoma
Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma
Prospective, interventional multicenter study evaluating adoptive cell therapy (ACT) via infusion of LN-144 (autologous TIL) followed by interleukin 2 (IL-2) after a nonmyeloablative lymphodepletion (NMA LD) preconditioning…
- Trial name
- LN-144 (NCT02360579)
- Testing
- Lifileucel
- Where
- 57 sites in United States, France and 6 more
- Volunteers
- 220 people
- Sponsor
- Iovance Biotherapeutics, Inc.
Benign Breast Neoplasm, Ductal Breast Carcinoma In Situ
Study of Docosahexaenoic Acid (DHA) in Triple Negative Breast Cancer Survivors
This randomized phase II trial studies how well docosahexaenoic acid works in preventing recurrence in breast cancer survivors. Docosahexaenoic acid supplement may prevent recurrence in breast cancer survivors.
- Conditions
- Benign Breast Neoplasm, Ductal Breast Carcinoma In Situ, Invasive Breast Carcinoma, Lobular Breast Carcinoma In Situ
- Trial name
- NCT01849250
- Testing
- Docosahexaenoic Acid
- Where
- 4 sites in United States
- Volunteers
- 65 people
- Sponsor
- National Cancer Institute (NCI)
Breast Tumor
Radiofrequency Chip for Localization of Non-Palpable Breast Lesions
The purpose of the project is to compare Radiofrequency identification device (RFID) localization technique with the current clinical standard wire localization technique.
- Trial name
- NCT03684408
- Testing
- RFID Localization, Wire Localization, RFID and Wire Localization
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- University of Missouri-Columbia
Breast Cancer
Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa
This research study is a Phase II clinical trial, which tests the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific cancer.
- Trial name
- NCT01796197
- Testing
- Trastuzumab, Pertuzumab, Paclitaxel
- Where
- 3 sites in United States
- Volunteers
- 23 people
- Sponsor
- Dana-Farber Cancer Institute
Locally Advanced Basal Cell Carcinoma, Skin Cancer
Phase II Study of Radiation Therapy and Vismodegib for Advanced Head/Neck Basal Cell Carcinoma
Chemotherapy, radiation therapy, and surgery are standard treatments for basal cell carcinoma at most institutions. The purpose of this study is to determine whether adding vismodegib to radiation (chemoradiotherapy) is safe and…
- Conditions
- Locally Advanced Basal Cell Carcinoma, Skin Cancer, Cutaneous Malignancy
- Trial name
- NCT01835626
- Testing
- Vismodegib, Radiation therapy
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Sue Yom
Breast Cancer
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
The objective of this study is to compare the progression-free survival (PFS) of the drug combination ramucirumab plus docetaxel to placebo plus docetaxel in previously untreated participants with human epidermal growth factor…
- Trial name
- NCT00703326
- Testing
- ramucirumab (IMC-1121B), docetaxel
- Where
- 232 sites in United States, Australia and 21 more
- Volunteers
- 1,144 people
- Sponsor
- Eli Lilly and Company
Breast Cancer, Cancer of the Breast
Comparing Letrozole Given Alone to Letrozole Given With Avastin in Post-Menopausal Women Breast Cancer
This purpose of this trial is to show that the combination of Avastin and hormone therapy should be more effective than hormone therapy alone for the treatment of breast cancer.
- Conditions
- Breast Cancer, Cancer of the Breast, Breast Neoplasm
- Trial name
- NCT00530868
- Testing
- Letrozole (Femara), Letrozole; Avastin
- Where
- 7 sites in United States
- Volunteers
- 75 people
- Sponsor
- University of Alabama at Birmingham
Metastatic Triple Negative Breast Cancer
Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated Metastatic Triple Negative Breast Cancer
This study will investigate the safety and efficacy of TIL therapy in patients with metastatic TNBC who have progressed on at least one and no more than three prior systemic anticancer therapies.
- Trial name
- NCT04111510
- Testing
- Tumor infiltrating lymphocytes (TIL) LN-145
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Yale University
Refractory Cutaneous Melanoma
Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma
The primary objective of this clinical trial is to evaluate the clinical efficacy and progression free survival of the triplet combination of ipilimumab + nivolumab + cabozantinib in patients with anti-PD-1/PD-L1 refractory…
- Trial name
- NCT05200143
- Testing
- Ipilimumab, Nivolumab, Cabozantinib
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Providence Health & Services
High Cholesterol, High Blood Pressure
Online Trial Examining Validity and Reliability of the Shared Decision Making Process Survey
The purpose of this study is to survey a sample of adults who have recently made a decision about treatment of high cholesterol or high blood pressure or a decision about screening for colorectal cancer, breast cancer, or…
- Conditions
- High Cholesterol, High Blood Pressure, Colorectal Cancer, Breast Cancer
- Trial name
- NCT04317690
- Where
- United States
- Volunteers
- 539 people
- Sponsor
- Massachusetts General Hospital
Metastatic Breast Cancer
A Study of Trastuzumab-Mcc-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer
Study of trastuzumab emtansine (T-DM1) administered to patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer.
- Trial name
- NCT00679211
- Testing
- Trastuzumab emtansine [Kadcyla]
- Volunteers
- 110 people
- Sponsor
- Genentech, Inc.
Breast Cancer, Ovarian Cancer
FPA150 in Patients With Advanced Solid Tumors
This is a multi-center study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of FPA150, an anti-B7H4 antibody alone or in combination with pembrolizumab an anti-PD1…
- Conditions
- Breast Cancer, Ovarian Cancer, Endometrial Cancer, Advanced Solid Tumors
- Trial name
- FPA150-001 (NCT03514121)
- Testing
- FPA150, Pembrolizumab
- Where
- 18 sites in United States, South Korea
- Volunteers
- 95 people
- Sponsor
- Five Prime Therapeutics, Inc.
Metastatic Breast Cancer, Recurrent Ovarian Carcinoma
Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics
This is an open-label, multi-center, phase I study designed to assess the maximum tolerated dose of ribociclib and belinostat in combination.
- Trial name
- CHARGE (NCT04315233)
- Testing
- Ribociclib, Belinostat
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- University of Utah
Neoplasms, Triple-Negative Breast Cancer
A Study Of PF-06647263 In Patients With Advanced Solid Tumors
To assess the safety and tolerability at increasing dose levels of PF-06647263 in patients with advanced solid tumors in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.
- Trial name
- NCT02078752
- Testing
- PF-06647263
- Where
- 10 sites in United States
- Volunteers
- 60 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.